Amycretin vs CT-388
Comparison of Amycretin (Moderate evidence) and CT-388 (Moderate evidence).
Last updated: February 12, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Amycretin
Dossier overview
CT-388
Dossier overview
Overview
Amycretin and CT-388 are both studied in the peptide research space.
Amycretin: A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk.
CT-388: A dual GLP-1/GIP receptor agonist acquired by Roche through the $2.
Evidence Comparison
| Aspect | Amycretin | CT-388 |
|---|---|---|
| Evidence Level | Moderate | Moderate |
| Human Studies | 8 | 6 |
| Preclinical Studies | 4 | 2 |
| Total Sources | 12 | 8 |
Key Differences
| Aspect | Amycretin | CT-388 |
|---|---|---|
| Category | Metabolic | Metabolic |
| Evidence Strength | Moderate | Moderate |
| Total Sources | 12 | 8 |
| Human Studies | 8 | 6 |
Summary
- Amycretin: Moderate evidence with 12 total sources (8 human)
- CT-388: Moderate evidence with 8 total sources (6 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.